Clinical Trials Logo

PTCL clinical trials

View clinical trials related to PTCL.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05967949 Recruiting - PTCL Clinical Trials

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Start date: April 1, 2023
Phase:
Study type: Observational

The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.

NCT ID: NCT04747236 Recruiting - PTCL Clinical Trials

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

PTCL
Start date: February 19, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of romidepsin and oral azacytidine to single agent drugs already determined effective in patients with PTCL. For the purposes of this study, the single agent drugs already used to treat lymphoma are called investigator's choice (IC), meaning the investigator will choose which one of these drugs to administer. The IC drug options include romidepsin, belinostat, pralatrexate or gemcitabine given alone. Funding Source: FDA OOPD.

NCT ID: NCT03900442 Recruiting - Advanced Cancer Clinical Trials

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Start date: September 1, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000 mg/m2 PTX-100 in patients with advanced malignancies. PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles unless toxicity is observed. Dose escalation is complete and the expansion is open and actively recruiting PTCL patients.

NCT ID: NCT03884205 Recruiting - Gemcitabine Clinical Trials

GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL

Start date: April 1, 2019
Phase:
Study type: Observational [Patient Registry]

Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. There is no standardized treatment protocol for this kind of lymphoma. So, clinical trials are encouraged by National Comprehensive Cancer Network (NCCN) for those patients. Former studies confirmed that GDP (Gemcitabine, Dexamethasone, and Cis-platinum) is superior with CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisone). Combination with etoposide can improve the outcome of some patients with high risk factors. The aim of our study is to compare the response and survival rate of GDPE/CEOPE (gemcitabine, cis-platinum, etoposide, and dexamethasone/cyclophosphamide, vincristine, pharmorubicin, etoposide, and prednisone) with those of CEOPE regimen, looking forward to its superiority in efficacy and safety for the newly diagnosed adult patients with PTCL.

NCT ID: NCT03240211 Recruiting - PTCL Clinical Trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Start date: February 2, 2022
Phase: Phase 1
Study type: Interventional

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.